Nicole Wittwer
Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.
Dr Nicole Wittwer is a Postdoctoral researcher in the Translational Oncology Laboratory at the Centre for Cancer Biology. She has a keen interest in the immune system and how we can modulate the immune system to fight back against cancer.
Dr Wittwer completed her PhD at the University of South Australia in the laboratory of Professor Angel Lopez, investigating the role of the stem cell marker CD123 in acute myeloid leukaemia. She then undertook a post-doctoral position at a highly successful Biotechnology company, Bionomics Ltd. As a member of the Oncology team, she worked on drug discovery and development programs and contributed to the identification and development of pharmacodynamic biomarkers directly in support of a phase I clinical trial in metastatic colorectal cancer.
Dr Wittwer is now based in the Translational Oncology Laboratory headed by Professor Michael Brown. The Translational Oncology Laboratory aims to develop new approaches to modulate the body’s immune system to more effectively target cancer cells and to translate these research discoveries into the clinic. Her research focuses on understanding how cancer cells override our immune defences and using this knowledge to develop therapeutic approaches to overcome immune resistance and sensitise cancer cells to therapy. Recent projects have focused on combining antibody drug conjugates with immunotherapy in breast and colon cancer in collaboration with Bristol Myers Squibb and the development of Chimeric Antigen Receptor (CAR) T-cells targeting a novel antigen in pancreatic cancer.
-
Education
Date Institution name Country Title University of South Australia Australia Doctor of Philosopy University of South Australia Australia Bachelor of Laboratory Medicine with Honours -
Research Interests
-
Journals
Year Citation 2024 Gargett, T., Truong, N. T. H., Gardam, B., Yu, W., Ebert, L. M., Johnson, A., . . . Brown, M. P. (2024). Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers. Journal for ImmunoTherapy of Cancer, 12(5), 17 pages.
Scopus12023 Wittwer, N. L., Staudacher, A. H., Liapis, V., Cardarelli, P., Warren, H., & Brown, M. P. (2023). An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer. Journal for ImmunoTherapy of Cancer, 11(3), 16 pages.
Scopus11 WoS1 Europe PMC72023 Wittwer, N. L., Brown, M. P., Liapis, V., & Staudacher, A. H. (2023). Antibody drug conjugates: hitting the mark in pancreatic cancer?. Journal of Experimental and Clinical Cancer Research, 42(1), 16 pages.
Scopus3 Europe PMC22022 Gargett, T., Ebert, L., Truong, N. T. H., Kollis, P., Sedivakova, K., Yu, W., . . . Brown, M. (2022). GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma.
2022 Nazarizadeh, A., Staudacher, A. H., Wittwer, N. L., Turnbull, T., Brown, M. P., & Kempson, I. (2022). Aluminium Nanoparticles as Efficient Adjuvants Compared to Their Microparticle Counterparts: Current Progress and Perspectives. International Journal of Molecular Sciences, 23(9), 15 pages.
Scopus19 WoS8 Europe PMC62022 Staudacher, A. H., Liapis, V., Wittwer, N. L., Tieu, W., Lam, H. C., Leusen, J., & Brown, M. P. (2022). Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMAB®. Biomedicine and Pharmacotherapy, 151, 113090-1-113090-10.
2022 Gargett, T., Ebert, L. M., Truong, N. T. H., Kollis, P. M., Sedivakova, K., Yu, W., . . . Brown, M. P. (2022). GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma. Journal for ImmunoTherapy of Cancer, 10(9), 1-15.
Scopus43 WoS15 Europe PMC332021 Liapis, V., Tieu, W., Wittwer, N. L., Gargett, T., Evdokiou, A., Takhar, P., . . . Staudacher, A. H. (2021). Positron emission tomographic imaging of tumor cell death using zirconium-89-labeled APOMAB® following cisplatin chemotherapy in lung and ovarian cancer xenograft models. Molecular Imaging and Biology, 23(6), 914-928.
Scopus6 WoS3 Europe PMC12021 Liapis, V., Tieu, W., Wittwer, N. L., Gargett, T., Evdokiou, A., Takhar, P., . . . Staudacher, A. H. (2021). Correction to: Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models (Molecular Imaging and Biology, (2021), 23, 6, (914-928), 10.1007/s11307-021-01620-1). Molecular Imaging and Biology, 23(6), 929.
2020 Staudacher, A. H., Liapis, V., Tieu, W., Wittwer, N., & Brown, M. P. (2020). Tumour-associated macrophages process drug and radio-conjugates of the dead tumour cell-targeting APOMAB® antibody. Journal of Controlled Release, 327, 779-787.
Scopus7 WoS6 Europe PMC62020 Liapis, V., Tieu, W., Rudd, S. E., Donnelly, P. S., Wittwer, N. L., Brown, M. P., & Staudacher, A. H. (2020). Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB®. EJNMMI Radiopharmacy and Chemistry, 5(1), 27-1-27-15.
Scopus10 WoS9 Europe PMC42017 Wittwer, N. L., Brumatti, G., Marchant, C., Sandow, J. J., Pudney, M. K., Dottore, M., . . . Ramshaw, H. S. (2017). High CD123 levels enhance proliferation in response to IL-3, but reduce chemotaxis by downregulating CXCR4 expression. Blood Advances, 1(15), 1067-1079.
Scopus26 WoS20 Europe PMC19 -
Conference Papers
Year Citation 2018 Inglis, D. J., Licari, J., Georgiou, K. R., Wittwer, N. L., Hamilton, R. W., Beaumont, D. M., . . . Lavranos, T. C. (2018). Characterization of BNC101 a human specific monoclonal antibody targeting the GPCR LGR5: First-in-human evidence of target engagement. In CANCER RESEARCH Vol. 78 (pp. 1 page). Chicago, IL: AMER ASSOC CANCER RESEARCH.
WoS22018 Inglis, D. J., Casolari, D. A., Tran, N., Beaumont, D. M., Wittwer, N. L., Ross, D., . . . Lavranos, T. C. (2018). The microtubule-disrupting drug BNC105 is a potent inducer of apoptosis in AML patient samples. In CANCER RESEARCH Vol. 78 (pp. 2 pages). Chicago, IL: AMER ASSOC CANCER RESEARCH.
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2024 Co-Supervisor Investigating dual targeting CAR-T cells for the treatment of brain tumours Doctor of Philosophy Doctorate Full Time Miss Abbey Rose Marshall
Connect With Me
External Profiles
